INGN 225

Drug Profile

INGN 225

Alternative Names: Ad.p53 DC vaccine; Adenovirus-p53 transduced dendritic cell vaccine; Autologous dendritic cell adenovirus p53 vaccine; Dendritic Cell based p53 Vaccine; P53 immunotherapy

Latest Information Update: 03 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator H. Lee Moffitt Cancer Center and Research Institute; Vanderbilt-Ingram Cancer Center
  • Developer H. Lee Moffitt Cancer Center and Research Institute; NewLink Genetics Corporation; University of Nebraska Medical Center
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants; P53 gene stimulants; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Small cell lung cancer

Most Recent Events

  • 23 Jan 2018 H. Lee Moffitt Cancer Center and Research Institute plans a phase II trial for Small Cell Lung Cancer (Second-line or greater therapy) in the US , (NCT03406715)
  • 03 Jan 2017 INGN 225 is still in phase II trials for Small cell lung cancer in USA (NCT00617409)
  • 03 Jun 2013 Phase-II clinical trials in Breast cancer (Combination therapy) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top